You are here : Home > BGE Lab > -- Gen&Chem team > CMBA platform

CMBA platform

Published on 27 June 2018

The CMBA: member of the CHEMBIOFRANCE national infrastructure
The Center for the screening for BioActive Molecules (CMBA) of the BGE laboratory participates to the recent very large research infrastructure (TGIR) ChemBioFrance. This infrastructure was designed to encourage and stimulate exchanges and services at the interfaces between the chemistry of biology and chemoinformatics in order to select bioactive molecules that can be used for basic or therapeutic research purposes. ChemBioFrance is a distributed infrastructure that interconnects the national chemical library, the platforms for the screening and the pharmacokinetic studies (ADME), and molecular modeling laboratories (chemoinformatics). It is open to researchers from academic and private laboratories.
Contact CEA/DRF/BIG: Marie-Odile Fauvarque
More information.

The CMBA platform, in partnership with the CCHD group (Chimie Combinatoire et Criblage à Haut Débit) based at CEA-Saclay (iBiTec) forms the G5C platform (Groupe de Chimie Combinatoire, Criblage Cellulaire et Chemogénomique) which is labeled by the GIS-IBiSA since 2008. G5C puts its expertise and instrumentation to the scientific community service for the discovery and synthesis of chemical molecules capable of interfering on living.

The CMBA pursues a triple objective:

• Facilities and collaborative activities for the High Throughput Screening (HTS) of chemicals libraries on cellular or biochemical assays, including statistical analysis of the results,
• A Research & Development activity for improving the analysis of cell phenotypes by High Content Screening imaging (HCS), including statistical analysis of results,
• A training activity on HTS and HCS.

The CMBA is widely open to the scientific community. Thus, since 2009, 25 screens were conducted for which 14 were made for teams of our institute. All fields of application in biology, health, bioenergy and environment are concerned with already selected molecules for their potential in treating cancer, infectious diseases, or in the production of 3rd generation bio-fuel.
The CMBA helps scientists in assessing the feasibility of a screening project, assists in the miniaturization of the test and then proceeds to the pilot test for the screening of a library of chemical molecules (small or medium scale). The pilot screen provides proof of concept of the relevance of the biological testing, the statistical robustness and its adaptability to an automated platform. A larger screen is then performed.

The CMBA is also part of the GDR3056 CNRS "ChemBioScreen" which brings together French academic platforms for screening molecules, research laboratories developing chemogenomics strategies and the "EU-Openscreen" network (European Infrastructure of Open Screening Platforms for Chemical Biology "Keys for Life Chemical's Locks").